Nonsteroidal Anti-Inflammatory Drugs: Exploiting Bivalent COXIB/ TP Antagonists for the Control of Cardiovascular Risk
Articolo
Data di Pubblicazione:
2017
Citazione:
Nonsteroidal Anti-Inflammatory Drugs: Exploiting Bivalent COXIB/ TP Antagonists for the Control of Cardiovascular Risk / S. Carnevali, C. Buccellati, B. Chiara, B. Massimo, G. Rovati, A. Sala. - In: CURRENT MEDICINAL CHEMISTRY. - ISSN 0929-8673. - 24:30(2017), pp. 3218-3230.
Abstract:
Nonsteroidal anti-inflammatory drugs (NSAIDs) are some of the most widely prescribed or dispensed over the counter analgesics and antipyretics that act by inhibiting prostaglandins and thromboxane synthesis. After the identification of a second isoform of COX, the pharmaceutical research focused on developing COX-2- selective drugs (COXIBs) considered as second generation NSAIDs that would retain the anti-inflammatory and analgesic activities of traditional NSAID without blunting the gastrointestinal cytoprotection sustained by COX1-derived products such as PGE2. However, while several clinical trials confirmed a gastrointestinal safer profile of COXIBs vs unselective COX inhibitors, increasing evidence for potential cardiovascular risk associated with COXIBs rapidly emerged. Today, there are no really safe NSAIDs to be used in chronic pain and anti-inflammatory treatments, as an adequate therapy associated with a minimal gastrointestinal damage and cardiovascular toxicity is yet to be developed.
Tipologia IRIS:
01 - Articolo su periodico
Keywords:
Arachidonic acid; COX-2 selective inhibitor; cardiovascular risk; multitarget drug; non steroidal antiinflammatory drug; thromboxane receptor antagonist
Elenco autori:
S. Carnevali, C. Buccellati, B. Chiara, B. Massimo, G. Rovati, A. Sala
Link alla scheda completa: